Hussman Strategic Advisors Inc. Sells 42,000 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Hussman Strategic Advisors cut its position in Catalyst Pharmaceuticals by 28.6% in the fourth quarter, selling 42,000 shares and now holding 105,000 shares valued at about $2.45 million (≈0.09% ownership).
• Analyst sentiment is bullish: the consensus rating is “Strong Buy” with a $34 average price target and recent upgrades and price-target increases (Citigroup raised its target to $35).
• Catalyst stock recently traded around $28.74, has a market cap of $3.51 billion and a P/E of 17.01, and is largely institutionally held (about 79.22% owned by institutions).

Hussman Strategic Advisors Inc. reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 28.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,000 shares of the biopharmaceutical company's stock after selling 42,000 shares during the period. Hussman Strategic Advisors Inc. owned approximately 0.09% of Catalyst Pharmaceuticals worth $2,451,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Rothschild Investment LLC grew its stake in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 1,520 shares during the period. Advisory Services Network LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Financial Life Planners bought a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $42,000. Finally, First Horizon Corp bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at approximately $52,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Up 2.2%

CPRX stock opened at $28.74 on Friday. The business's fifty day moving average is $24.91 and its 200-day moving average is $23.69. The company has a market cap of $3.51 billion, a P/E ratio of 17.01, a price-to-earnings-growth ratio of 0.93 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56.

Wall Street Analyst Weigh In

CPRX has been the topic of a number of research analyst reports. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Friday, March 27th. Zacks Research upgraded Catalyst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, March 3rd. Citigroup increased their price target on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, March 3rd. Truist Financial upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings restated a "buy (b-)" rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Three equities research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and a consensus price target of $34.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company's mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company's lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.